The approach was finally applied for the quantification of an in-house calibrant for the Alzheimer’s disease biomarker tau protein, and the result was verified by aromatic amino acid analysis (AAAA), a variant of amino acid analysis, which requires no derivatization step [12]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.